Simultaneously, subpopulations of tumor cells with ROS1 rearrangement, which were not initially detected, may gradually expand and become the dominant clone within the tumor population due to their resistance to pembrolizumab, thus being discovered in subsequent testing. This evidence concerns the gene ROS1 and neoplasm.